The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Open accessAbstract
Multiple myeloma accounts for approximately 10% of hematologic malignancies.The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB (hyper c alcemia, r enal failure, a nemia, or lytic b one lesions) features felt related to the plasma cell disorder, bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥100 (provided involved FLC is ≥100 mg/L), or >1 focal lesion on magnetic resonance imaging. Patients with del(17p), t(14;16), and t(14;20) have high‐risk multiple myeloma. Patients with t(4;14) translocation and gain(1q) have intermediate‐risk. All others are considered standard‐risk. Initial treatment consists of bortezomib, lenalidomide, dexamethasone (VRD). In high‐risk patients, carfilzomib, lenalidomide, dexamethasone (KRD) is an alternative to VRD. In eligible patients, initial therapy is given for approximately 3–4 months followed by autologous stem cell transplantation (ASCT). Standard risk patients can opt for delayed ASCT at first relapse. Patients not candidates for transplant are treated with Rd until progression, or alternatively, a triplet regimen such as VRD for approximately 12–18 months. After ASCT, lenalidomide maintenance is considered for standard risk patients especially in those who are not in very good partial response or better, while maintenance with a bortezomib‐based regimen is needed for patients with intermediate or high‐risk disease. Patients with indolent relapse can be treated with 2‐drug or 3‐drug combinations. Patients with more aggressive relapse require a triplet regimen or a combination of multiple active agents. Am. J. Hematol. 91:720–734, 2016. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationPalumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationTtal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Self-citationKumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Self-citationClinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Self-citationMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Facon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 869
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Self-citationRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Kyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 855
Self-citationLonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citationSonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815
Self-citationPalumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 809
Miguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 801
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
San-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 741
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citationMaintenance therapy with thalidomide improves survival in patients with multiple myeloma
Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Agha, I. Y., Bourhis, J.-H., Garderet, L., Pegourie, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 667
Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 657
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citationOrlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 645
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Self-citationHideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 593
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Self-citationA monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 569
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Kim, J. H., Kim, J. W., Kim, Y. N., Kim, H. I., Kim, J. Y., Kwon, G. Y., Kim, K., & Jang, H. R. (2015) · Case Reports in Nephrology and Dialysis · doi:10.1159/000439267 · Cited by 538
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationA Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
Self-citationBarlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Moore, D. F., Dakhil, S. R., Lanier, K. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5807 · Cited by 495
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Dimopoulos, M., Terpos, E., Comenzo, R. L., Tosi, P., Beksac, M., Sezer, O., Siegel, D., Lokhorst, H., Kumar, S., Rajkumar, S. V., et al. (2009) · Leukemia · doi:10.1038/leu.2009.89 · Cited by 482
Self-citationChromosome translocations in multiple myeloma
Bergsagel, P. L., & Kuehl, W. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204641 · Cited by 478
Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., PALVA, I. P., Oivanen, T. M., Corrado, C., et al. (1998) · Journal of Clinical Oncology · Cited by 470
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446
Self-citationMateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 433
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550020 · Cited by 425
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422683 · Cited by 423
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Dispenzieri, A., Katzmann, J. A., Kyle, R. A., Larson, D. R., Melton, L. J., Colby, C. L., Therneau, T. M., Clark, R., Kumar, S. K., Bradwell, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60482-5 · Cited by 394
Self-citationRichardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J.-P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 381
Reeder, C. B., Reece, D. E., Kukreti, V, Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N. A., Spong, J. E., Piza, J. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 372
Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2509 · Cited by 370
Clinical Course of Patients With Relapsed Multiple Myeloma
Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365
Self-citationKumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404801 · Cited by 351
Self-citationGenomic abnormalities in monoclonal gammopathy of undetermined significance
Fonseca, R., Bailey, R. J., Ahmann, G. J., Rajkumar, S. V., Hoyer, J. D., Lust, J. A., Kyle, R. A., Gertz, M. A., Greipp, P. R., & Dewald, G. W. (2002) · Blood · doi:10.1182/blood.v100.4.1417.h81602001417_1417_1424 · Cited by 348
Self-citationRajkumar, S. V., Rosiñol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Self-citationHarousseau, J., Attal, M., Leleu, X. P., Troncy, J., Pegourié, B., Stoppa, A., Hulin, C., Benboubker, L., Fuzibet, J., Renaud, M., et al. (2006) · PubMed · Cited by 334
Spencer, A., Prince, H. M., Roberts, A. W., Prosser, I. W., Bradstock, K. F., Coyle, L., Gill, D. S., Horvath, N., Reynolds, J., & Kennedy, N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8573 · Cited by 332
Barlogie, B., Anaissie, E., Van Rhee, F., Haessler, J., Hollmig, K., Pineda‐Roman, M., Cottler‐Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06639.x · Cited by 331
Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., Rossi, D., Gentilini, F., Crippa, C., Galli, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6844 · Cited by 323
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317
Self-citationMoreau, P., Avet-Loiseau, H., Facon, T., Attal, M., Tiab, M., Hulin, C., Doyen, C., Garderet, L., Randriamalala, E., Araujo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355081 · Cited by 303
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Paiva, B., van Dongen, J. J. M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2014-11-568907 · Cited by 299
Rajkumar, S. V. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.63 · Cited by 289
Self-citationLarocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2012) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 288
Krishnan, A., Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70243-1 · Cited by 274
Fayers, P. M., Palumbo, A., Hulin, C., Waage, A., Wijermans, P., Beksaç, M., Bringhen, S., Mary, J.-Y., Gimsing, P., Termorshuizen, F., et al. (2011) · Blood · doi:10.1182/blood-2011-03-341669 · Cited by 272
Rajkumar, S. V., Landgren, O., & Mateos, M.-V. (2015) · Blood · doi:10.1182/blood-2014-09-568899 · Cited by 269
Self-citationWijermans, P., Schaafsma, M., Termorshuizen, F., Ammerlaan, R., Wittebol, S., Sinnige, H., Zweegman, S., van Marwijk Kooy, M., van der Griend, R., Lokhorst, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1610 · Cited by 260
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
Kumar, S., Fonseca, R., Ketterling, R. P., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dingli, D., Knudson, R. A., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390658 · Cited by 253
Self-citationDurie, B. G. M., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0311-8 · Cited by 253
Self-citationRajkumar, S. V., Gupta, V, Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., Ketterling, R. P., Lust, J. A., Kyle, R. A., & Kumar, S. K. (2013) · Leukemia · doi:10.1038/leu.2013.86 · Cited by 239
Self-citationKumar, S., Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Lentzsch, S., Munshi, N., Niesvizky, R., et al. (2009) · Blood · doi:10.1182/blood-2009-04-205013 · Cited by 234
Self-citationNeben, K., Jauch, A., Hielscher, T., Hillengass, J., Lehners, N., Seckinger, A., Granzow, M., Raab, M. S., Ho, A. D., Goldschmidt, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4923 · Cited by 233
Landgren, O., & Weiss, B. M. (2009) · Leukemia · doi:10.1038/leu.2009.134 · Cited by 231
Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Kumar, S., Munshi, N. C., Dispenzieri, A., Kyle, R., et al. (2009) · Leukemia · doi:10.1038/leu.2009.127 · Cited by 231
Self-citationMelphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Waage, A., Gimsing, P., Fayers, P., Abildgaard, N., Ahlberg, L., Björkstrand, B., Carlson, K., Dahl, I. M., Forsberg, K., Gulbrandsen, N., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237974 · Cited by 230
Lacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348896 · Cited by 222
Self-citationHjorth, M., Hellquist, L., Holmberg, E., Magnusson, B., Rödjer, S., & Westin, J. (1993) · European Journal of Haematology · doi:10.1111/j.1600-0609.1993.tb00148.x · Cited by 220
Interpretation of cytogenetic results in multiple myeloma for clinical practice
Rajan, A. M., & Rajkumar, S. V. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.92 · Cited by 219
Self-citationKatzmann, J. A., Dispenzieri, A., Kyle, R. A., Snyder, M. R., Plevak, M. F., Larson, D. R., Abraham, R. S., Lust, J. A., Melton, L. J., & Rajkumar, S. V. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.12.1575 · Cited by 215
Self-citationRegelink, J. C., Minnema, M. C., Terpos, E., Kamphuis, M. H., Raijmakers, P. G., Pieters – van den Bos, I. C., Heggelman, B. G. F., Nievelstein, R., Otten, R. H. J., van Lammeren – Venema, D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12346 · Cited by 211
Short, K. D., Rajkumar, S. V., Larson, D., Buadi, F., Hayman, S., Dispenzieri, A., Gertz, M., Kumar, S., Mikhael, J., Roy, V, et al. (2011) · Leukemia · doi:10.1038/leu.2011.29 · Cited by 209
Self-citationMultiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 208
Self-citationLudwig, H., Hajek, R., Tóthová, E., Drach, J., Adam, Z., Labar, B., Egyed, M., Spicka, I., Gisslinger, H., Greil, R., et al. (2009) · Blood · doi:10.1182/blood-2008-07-169565 · Cited by 208
Landgren, O., Graubard, B. I., Katzmann, J. A., Kyle, R. A., Ahmadizadeh, I., Clark, R., Kumar, S. K., Dispenzieri, A., Greenberg, A. J., Therneau, T. M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.34 · Cited by 208
Self-citationNair, B., van Rhee, F., Shaughnessy, J. D., Anaissie, E., Szymonifka, J., Hoering, A., Alsayed, Y., Waheed, S., Crowley, J., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2009-11-255620 · Cited by 201
Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., & Melton, L. J. (2004) · Cancer · doi:10.1002/cncr.20652 · Cited by 201
Self-citationLacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.190 · Cited by 197
Self-citationRichardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2679 · Cited by 162
Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedè, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563759 · Cited by 154
Miguel, J. F. S., Richardson, P. G. G., Günther, A., Sezer, O., Siegel, D. S. D., Bladé, J., LeBlanc, R., Sutherland, H. J., Sopala, M., Mishra, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.7068 · Cited by 148
Beksaç, M., Haznedar, R., Firatli‐Tuglular, T., Özdoğu, H., Aydoğdu, İ., Konuk, N., Sucak, G. T., Kaygusuz, I., Karakuş, S., Kaya, E., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01524.x · Cited by 143
Pineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J., et al. (2008) · Leukemia · doi:10.1038/leu.2008.99 · Cited by 139
Therneau, T. M., Kyle, R. A., Melton, L. J., Larson, D. R., Benson, J. T., Colby, C. L., Dispenzieri, A. A., Kumar, S. K., Katzmann, J. A., Cerhan, J. R., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.06.014 · Cited by 138
Self-citationApproach to the treatment of multiple myeloma: a clash of philosophies
Rajkumar, S. V., Gahrton, G., & Bergsagel, P. L. (2011) · Blood · doi:10.1182/blood-2011-06-297853 · Cited by 138
Self-citationNew insights into the pathophysiology of multiple myeloma
Seidl, S., Kaufmann, H., & Drach, J. W. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01195-1 · Cited by 135
Rajkumar, S. V., Harousseau, J., Durie, B. G. M., Anderson, K. C., Dimopoulos, M. A., Kyle, R. A., Bladé, J., Richardson, P. G. G., Orlowski, R. Z., Siegel, D. S. D., et al. (2011) · Institutional Research Information System University of Turin (University of Turin) · Cited by 131
Self-citationAttal, M., Lauwers‐Cancès, V., Hulin, C., Facon, T. T. F., Caillot, D., Escoffre‐Barbe, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2015) · Blood · doi:10.1182/blood.v126.23.391.391 · Cited by 127
Management of multiple myeloma: a systematic review and critical appraisal of published studies
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01077-5 · Cited by 113
van Rhee, F., Szymonifka, J. D., Anaissie, E. J., Nair, B. P., Waheed, S., Alsayed, Y. M., Petty, N. M., Shaughnessy, J. D., Hoering, A., Crowley, J. J., et al. (2010) · Blood · doi:10.1182/blood-2010-01-264333 · Cited by 109
The molecular characterization and clinical management of multiple myeloma in the post-genome era
Zhou, Y., Barlogie, B., & Shaughnessy, J. D. (2009) · Leukemia · doi:10.1038/leu.2009.160 · Cited by 108
Kapoor, P., Rajkumar, S. V., Dispenzieri, A. A., Gertz, M. A., Lacy, M. Q., Dingli, D., Mikhael, J. R., Roy, V., Kyle, R. A., Greipp, P. R., et al. (2011) · Leukemia · doi:10.1038/leu.2010.313 · Cited by 106
Self-citationWitzig, T. E., Laumann, K. M., Lacy, M. Q., Hayman, S. R., Dispenzieri, A. A., Kumar, S. K., Reeder, C. B., Roy, V., Lust, J. A., Gertz, M. A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.236 · Cited by 101
Self-citationHari, P. N., Zhang, M.-J., Roy, V, Pérez, W. S., Bashey, A., To, L. B., Elfenbein, G., Freytes, C. O., Gale, R. P., Gibson, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.61 · Cited by 100
Stewart, A. K., Jacobus, S. J., Fonseca, R., Weiss, M., Callander, N. S., Chanan-Khan, A. A., & Rajkumar, S. V. (2015) · Blood · doi:10.1182/blood-2014-12-613927 · Cited by 91
Self-citationTransplantation for multiple myeloma: who, when, how often?
(2003) · Blood · doi:10.1182/blood-2003-01-0073 · Cited by 88
Many facets of bortezomib resistance/susceptibility
Kumar, S. K., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2008-07-167767 · Cited by 83
Self-citationMultiple myeloma and the road to personalised medicine
Russell, S. J., & Rajkumar, S. V. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70143-7 · Cited by 75
Self-citationTreatment of Myeloma: Cure vs Control
Rajkumar, S. V. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.10.1142 · Cited by 75
Self-citationA prognostic index for multiple myeloma
Grignani, G., Gobbi, P., Formisano, R., Pieresca, C., Ucci, G., Brugnatelli, S., Riccardi, A., & Ascari, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.212 · Cited by 73
Moreau, P., Masszi, T., Grząśko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P. S., Baker, B. W., Jackson, S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.727.727 · Cited by 68
Durie, B. G. M., Hoering, A., Rajkumar, S. V., Abidi, M. H., Epstein, J., Kahanic, S. P., Thakuri, M. C., Reu, F. J., Reynolds, C. M., Sexton, R., et al. (2015) · Blood · doi:10.1182/blood.v126.23.25.25 · Cited by 56
Self-citationPaiva, B., Chandia, M., Puig, N., Vídriales, M., Perez, J. J., López‐Corral, L., Ocio, E. M., García‐Sánz, R., Gutierrez, N. C., Ubieto, A. J., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.115162 · Cited by 54
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
Gutman, D., Morales, A. A., & Boise, L. H. (2009) · Leukemia · doi:10.1038/leu.2009.123 · Cited by 53
Myeloma bone disease: Pathogenetic mechanisms and clinical assessment
Silvestris, F., Lombardi, L., Matteo, M. D., Bruno, A., & Dammacco, F. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.04.014 · Cited by 53
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
Vu, T., Gonsalves, W., Kumar, S., Dispenzieri, A., Lacy, M. Q., Buadi, F., Gertz, M. A., & Rajkumar, S. V. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.91 · Cited by 51
Self-citationEvolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview
Jakubowiak, A. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.005 · Cited by 48
Mateos, M., Oriol, A., Martínez‐López, J., Cibeira, M. T., Gutierrez, N. C., Terol, M. J., de Paz, R., García‐Laraña, J., Bengoechea, E., Martı́n, A., et al. (2009) · Blood · doi:10.1182/blood.v114.22.3.3 · Cited by 45
Korde, N., Zingone, A., Kwok, M., Manasanch, E. E., Bhutani, M., Tageja, N., Kazandjian, D. G., Mailankody, S., Costello, R., Zhang, Y., et al. (2013) · Blood · doi:10.1182/blood.v122.21.538.538 · Cited by 39
Moreau, P., Hulin, C., Marit, G., Caillot, D., Facon, T., Lenain, P., Berthou, C., Pégourié, B., Stoppa, A. M., Casassus, P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.82 · Cited by 39
Reduced-intensity allogeneic transplantation for myeloma: reality bites
Stewart, A. K. (2009) · Blood · doi:10.1182/blood-2008-12-173526 · Cited by 35
Biochemical markers of bone turnover in diagnosis of myeloma bone disease
Dızdar, Ö., Barışta, İ., Kalyoncu, U., Karadağ, Ö., Hasçelik, G., Cila, A., Pinar, A., Celik, I., Kars, A., & Tekuzman, G. (2006) · American Journal of Hematology · doi:10.1002/ajh.20794 · Cited by 32
Fermand, J., Desseaux, K., & Marolleau, J. P. (2009) · Blood · doi:10.1182/blood.v114.22.2320.2320 · Cited by 26
Panobinostat for the treatment of multiple myeloma
Rajkumar, S. V. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70443-7 · Cited by 23
Self-citationPalumbo, A. P., Magarotto, V., Bringhen, S., Offidani, M., Pietrantuono, G., Liberati, A. M., Benevolo, G., Ledda, A., Gilestro, M., Galli, M., et al. (2013) · Blood · doi:10.1182/blood.v122.21.536.536 · Cited by 20
Moreau, P., Hulin, C., Macro, M., Caillot, D., Chaleteix, C., Roussel, M., Garderet, L., Royer, B., Bréchignac, S., Tiab, M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.393.393 · Cited by 20
Lenalidomide maintenance—perils of a premature denouement
Rajkumar, S. V. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.100 · Cited by 15
Self-citation
Cited by
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 571
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Ledergor, G., Weiner, A., Zada, M., Wang, S.-Y., Cohen, Y. C., Gatt, M. E., Snir, N., Magen, H., Koren-Michowitz, M., Herzog-Tzarfati, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0269-2 · Cited by 263
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166
Miller, A., Asmann, Y., Cattaneo, L., Braggio, E., Keats, J., Auclair, D., Lonial, S., The MMRF CoMMpass Network, Russell, S. J., & Stewart, A. K. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.94 · Cited by 145
Metadata
- Authors
- Rajkumar, S. V.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2016-06-12
- Volume
- 91
- Issue
- 7
- Pages
- 719-734
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2425909334
- Cited by
- 456
- References
- 159
- FWCI
- 50.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.